Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 22, 2004. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to corporate governance disclosures regarding share ownership.
Material Changes
The primary material change reported is a transfer of shares within the GlaxoSmithKline Employee Trust ("GSK Trust"). On September 20, 2004, Abacus (GSK) Trustees Limited transferred 103,980 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991. The company was advised of this transaction on September 21, 2004.
Management Commentary and Risks
The filing notes that the GSK Trust is a discretionary trust where all current and former employees are potential beneficiaries. Consequently, three directors—Dr J-P Garnier, Dr T Yamada, and Mr J D Coombe—are interested in the shares held in the GSK Trust in the same capacity as other employees. No specific risks, contingencies, or unusual financial items are detailed in this text.
Investor Verification Points
- Verify the total number of shares held in the GSK Trust following the September 20, 2004 transfer.
- Confirm the specific shareholding changes for directors Dr J-P Garnier, Dr T Yamada, and Mr J D Coombe resulting from the trust distribution.
- Review the terms of the SmithKline Beecham Employee Share Option Plan 1991 to understand the vesting conditions for the 103,980 transferred shares.